Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pill vs. IV: could a new drug beat the standard for deadly lung fungus?

NCT ID NCT05468372

Disease control Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether the antifungal drug posaconazole (taken as a pill) works as well as the standard IV drug amphotericin B for treating a serious lung infection called pulmonary mucormycosis. The trial involved 82 adults with this rare but deadly infection. Researchers compared how many patients improved after six weeks of treatment with either drug.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Posaconazole (an antifungal drug) compared to amphotericin B (standard antifungal)
What this could lead to
If posaconazole works as well as amphotericin B, it could offer a safer, pill-based treatment for this serious lung infection, avoiding the need for IV therapy.
What could go wrong
This is a small, phase 2 trial with only 82 participants. Posaconazole may not be as effective as the standard treatment, and the results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

82 people

The number who actually took part.

Started

Jul 2022

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

13 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Subjects with proven or probable pulmonary mucormycosis. Participants with a suspicion of pulmonary mucormycosis (as defined previously) based on compatible clinical presentation and compatible imaging will be screened for inclusion in the study. Exclusion Criteria: * Failure to provide informed consent * Contraindications or hypersensitivity to amphotericin B, posaconazole or their components * Already received \>4 days of antifungals prior to randomization into the study * Pregnant women * High chances of mortality within 48 hours of enrolment into the study Subjects with possible pulmonary mucormycosis will also be excluded, if their diagnosis is not confirmed within four working days of enrollment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mucormycosis; pulmonary (etiology) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Zygomycosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mucormycosis; pulmonary (etiology)

Contacts and locations

Locations

  • Postgraduate Institute of Medical Education and Research

    Chandigarh, Chandigarh, 160012, India